My Cancer Genome: Genetically Informed Cancer Medicine

  • Home
  • DIRECT
  • About Us
  • Acute Myeloid Leukemia
  • CALR
    • CALR c.1154_1155insTTGTC (K385fs*47)
    • CALR c.1099_1150del (L367fs*46)
  • CBFB-MYH11
    • CBFB-MYH11 Inversion
    • CBFB-MYH11 Translocation
  • CEBPA
    • CEBPA Biallelic Mutation
  • DEK-NUP214
    • DEK-NUP214 Fusion
  • DNMT3A
    • DNMT3A c.2644C>T (R882C)
    • DNMT3A c.2644C>G (R882G)
    • DNMT3A c.2644C>A (R882S)
    • DNMT3A c.2645G>A (R882H)
    • DNMT3A c.2645G>T (R882L)
    • DNMT3A c.2645G>C (R882P)
  • FLT3
    • FLT3 ITD
    • FLT3 c.2503G>C (D835H)
    • FLT3 c.2503G>A (D835N)
    • FLT3 c.2503G>T (D835Y)
    • FLT3 c.2504A>C (D835A)
    • FLT3 c.2504A>T (D835V)
    • FLT3 c.2505T>A (D835E)
    • FLT3 c.2505T>G (D835E)
    • FLT3 c.2506A>T (I836F)
    • FLT3 c.2506A>C (I836L)
    • FLT3 c.2506A>G (I836V)
    • FLT3 c.2506_2507delATinsGA (I836D)
    • FLT3 c.2506_2507delATinsCA (I836H)
    • FLT3 c.2508C>G (I836M)
  • IDH1
    • IDH1 c.394C>T (R132C)
    • IDH1 c.394C>G (R132G)
    • IDH1 c.394C>A (R132S)
    • IDH1 c.395G>A (R132H)
    • IDH1 c.395G>T (R132L)
    • IDH1 c.395G>C (R132P)
  • IDH2
    • IDH2 c.418C>G (R140G)
    • IDH2 c.418C>T (R140W)
    • IDH2 c.419G>T (R140L)
    • IDH2 c.419G>A (R140Q)
    • IDH2 c.515G>A (R172K)
    • IDH2 c.515G>T (R172M)
    • IDH2 c.516G>C (R172S)
  • KIT
    • KIT Exon 8 Mutation
    • KIT c.2446G>C (D816H)
    • KIT c.2446G>T (D816Y)
    • KIT c.2446_2447delGAinsAT (D816I)
    • KIT c.2447A>T (D816V)
  • MLL-MLLT3
    • MLL-MLLT3 Fusion
  • NPM1
    • NPM1 Exon 12 Mutations
  • PML-RARA
    • PML-RARA Fusion
  • RBM15-MKL1
    • RBM15-MKL1 Fusion
  • RPN1-EVI1
    • RPN1-EVI1 Inversion
    • RPN1-EVI1 Translocation
  • RUNX1-RUNX1T1
    • RUNX1-RUNX1T1 Fusion
  • TET2
    • TET2 Mutations
  • Other Diseases
    • Acute Lymphoblastic Leukemia
    • Anaplastic Large Cell Lymphoma
    • Basal Cell Carcinoma
    • Bladder Cancer
    • Breast Cancer
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
    • Colorectal Cancer
    • GIST
    • Gastric Cancer
    • Glioma
    • Inflammatory Myofibroblastic Tumor
    • Lung Cancer
    • Medulloblastoma
    • Melanoma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
    • Neuroblastoma
    • Ovarian Cancer
    • Prostate Cancer
    • Rhabdomyosarcoma
    • Thymic Carcinoma
    • Thyroid Cancer
    • Waldenstrom Macroglobulinemia
  • Molecular Medicine
    • Anticancer Agents
    • Circulating Tumor DNA
    • Detecting Gene Alterations in Cancers
    • Immunotherapy in Cancer
    • Overview of Targeted Therapies for Cancer
    • Pathways
    • Types of Molecular Tumor Testing
  • Take Our Survey
  • Glossary
  • News
  • Our Team
  • Acknowledgements
  • What is RBM15-MKL1?
  • RBM15-MKL1 in Acute Myeloid Leukemia
  • Clinical Trials

RBM15-MKL1

RNA binding motif protein 15 (RBM15) is a gene that encodes for a protein with repressor function in several signaling pathways (Gene 2013a). In cancer, rearrangements involving RBM15 have been observed in AML. Its role is also being investigated in other cancers.

Megakaryoblastic leukemia (translocation) 1 (MKL1) is a gene that encodes a protein that interacts with myocardin (Gene 2013b​). In cancer, rearrangements involving MKL1 have been observed in AML. Its role is also being investigated in other cancers.

The RBM15-MKL1 fusion has been observed in AML, particularly acute megakaryoblastic leukemia.

Related Pathways

  • Chromatin remodeling/DNA methylation
​

Contributors: Adam Seegmiller, M.D., Ph.D., Madan Jagasia, M.B.B.S., M.S.

Suggested Citation: Seegmiller, A., M. Jagasia. 2015. RBM15-MKL1. My Cancer Genome https://www.mycancergenome.org/content/disease/acute-myeloid-leukemia/rbm15-mkl1/?tab=0 (Updated December 4).

Last Updated: December 4, 2015

RBM15-MKL1 Fusion Gene in Acute Myeloid Leukemia

The RBM15-MKL1 fusion gene, t(1;22)(p13;q13), is rarely observed in AML but is associated with megakaryoblastic leukemia. The fusion protein has been shown in preclinical studies to disrupt Notch signaling and cytokine signaling (Mercher et al. 2009).

​​​

Contributors: Adam Seegmiller, M.D., Ph.D., Madan Jagasia, M.B.B.S., M.S., Scott Wheeler, Ph.D. (through June 2014), Cindy L. Vnencak-Jones, Ph.D.

Suggested Citation: Seegmiller, A., M. Jagasia, S. Wheeler, C. Vnencak-Jones. 2013. RBM15-MKL1 Fusion Gene in Acute Myeloid Leukemia. My Cancer Genome https://www.mycancergenome.org/content/disease/acute-myeloid-leukemia/rbm15-mkl1/ (Updated September 9).

Last Updated: September 9, 2013

My Cancer Genome has released its new and improved cancer clinical trials search tool on our beta website. Please visit beta.mycancergenome.org to check it out!

Disclaimer: The information presented at MyCancerGenome.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.

  • MCG Home |
  • About Us |
  • Acknowledgments |
  • Give |
  • Site Map |
  • Legal |
  • APIs and Licensing
My Cancer Genome is managed by the Vanderbilt-Ingram Cancer Center   Copyright © 2010 - 2019 MY CANCER GENOME